ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGEM vs ODTX // PIOTROSKI F-SCORE QUALITY

Cullinan Therapeutics Inc. (NASDAQ) VS. Odyssey Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CGEM 1 — ODTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEM VS. ODTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGEM ODTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -17.68% — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 48.9 -3.62 ODTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $994.3M $953.0M $41.3M CGEM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGEM REV ODTX REV CGEM GROSS % ODTX GROSS % CGEM FCF ODTX FCF
FY 2025 $0 $0 — — -$175.8M —
FY 2024 $0 — — — -$145.3M —
FY 2023 $0 — — — -$134.3M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEM // BETA —
ODTX // BETA —